SIGA Technologies Inc
SIGA
查看详细走势图
5.300USD
+0.340+6.85%
收盘 03/27, 16:00（美东）报价延迟15分钟
273.68M总市值
16.29市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.85%
5天
+7.29%
1月
-18.08%
6月
-40.85%
今年开始到现在
-13.26%
1年
+5.46%
查看详细走势图
TradingKey SIGA Technologies Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
SIGA Technologies Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力稳定。当前估值合理，在药品行业排名114/157位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
SIGA Technologies Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
SIGA Technologies Inc亮点
亮点风险
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
业绩增长期
公司处于发展阶段，最新年度总收入94.57M美元
高分红
公司属于高分红公司，最新股息支付率72.80%
估值高估
公司最新PE估值16.29，处于3年历史高位
机构减仓
最新机构持股35.82M股，环比减少8.49%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值95.76K
活跃度增加
近期活跃度增加，过去20天平均换手率-0.00
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
SIGA Technologies Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
SIGA Technologies Inc简介
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
公司代码SIGA
公司SIGA Technologies Inc
CEONguyen (Diem)
网址https://www.siga.com/
相关品种
